We provide you with 20 years of free, institutional-grade data for ITOS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ITOS. Explore the full financial landscape of ITOS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about ITOS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
iTeos Therapeutics, Inc(NASDAQ:ITOS) 
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a...
Website: http://www.iteostherapeutics.com
Founded: 2012
Full Time Employees: 55
CEO: Michel Detheux
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends